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Abstract  
Purpose 
The purpose of this study was to evaluate the cost effectiveness of adding bevacizumab 
to capecitabine monotherapy in patients with metastatic colorectal cancer.  
Methods 
Individual patient level data on resource use and progression free survival were 
prospectively collected in the Phase III MAX trial. Resource use data were collected for 
the period between randomisation and disease progression, and unit costs were assigned 
from the perspective of the Australian health care funder. Effectiveness was measured 
in quality adjusted progression free survival years, with utility scores obtained from 
both the community valued EQ-5D questionnaire and the patient valued UBQ-C 
questionnaire.  Progression free survival was used as a secondary effectiveness 
measure. 
Results 
The addition of bevacizumab to capecitabine monotherapy cost approximately 
$192,156 (95% confidence interval [CI], $135,619 to $326,894) per quality adjusted 
progression free survival year gained when using publicly listed pharmaceutical prices 
and utility values from the EQ-5D questionnaire. This decreased to $149,455 (95% CI, 
$100,356 to $245,910) when values from the UBQ-C questionnaire were applied. The 
incremental cost per progression free survival year was $145,059 (95% CI, $106,703 to 
$233,225). 
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Conclusions 
Bevacizumab was not found to be cost effective at its listed price, based on results from 
the MAX trial. 
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Introduction 
Colorectal cancer is the second most common cause of cancer death in Australia behind 
lung cancer, accounting for 2,856 deaths in 2010.
1,2
 Although there have been advances 
in the treatment of metastatic colorectal cancer, most patients continue to have 
incurable disease. Accordingly there has been an imperative to develop and evaluate 
promising new treatments that may provide improved health outcomes over standard 
chemotherapy.  The introduction of a new medical treatment for cancer is often costly 
and it is important to ensure that where public funds are limited, those treatments which 
represent the best value for money are identified.
3
   
The MAX trial evaluated the effect of adding bevacizumab, with or without mitomycin 
C, to capecitabine as initial treatment for patients with metastatic colorectal cancer.
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Consistent with the results of other randomised studies of bevacizumab in the 1st and 
2nd line setting of advanced colorectal cancer,
5-7
 the MAX study demonstrated an 
improvement in progression free survival (PFS), the trial’s primary outcome. However, 
the treatment was not found to have a significant impact on the response rate (RR) or 
overall survival (OS).  
Based on the clinical data, bevacizumab has been approved in Australia and globally for 
the treatment of advanced colorectal cancer.
8
 However, there have been no prospective 
analyses of its cost-effectiveness.  A number of small retrospective studies assessing the 
cost-effectiveness of bevacizumab in different treatment contexts have generally 
concluded that the treatment is not likely to be cost-effective.
9-12
  
The aim of this study was to determine the cost effectiveness of adding bevacizumab to 
capecitabine monotherapy in patients with untreated metastatic colorectal cancer, using 
data from the prospective economic evaluation conducted alongside the MAX trial.  
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 Methods 
An economic evaluation from the perspective of the Australian health care funder  was 
performed using individual patient level data from the previously reported MAX trial.
4
  
Study parameters: 
The MAX trial was an open label, multicentre, phase III randomised study sponsored 
by the Australasian Gastro-Intestinal Trials Group (AGITG), conducted at 43 
institutions in Australia, New Zealand and the United Kingdom.  
A total of 471 patients with previously untreated, unresectable metastatic colorectal 
cancer were randomly assigned to three groups: capecitabine; capecitabine plus 
bevacizumab; or capecitabine, bevacizumab and mitomycin C. Treatment was planned 
to continue until confirmed disease progression. Capecitabine plus bevacizumab, with 
or without mitomycin C, was compared with capecitabine alone for progression free 
survival after a median follow up of 31 months.   
Economic methods: 
As the MAX trial found no significant treatment difference with the addition of 
mitomycin C to bevacizumab and capecitabine, the cost of mitomycin was excluded 
from this study and the primary analysis focused on the cost effectiveness of 
bevacizumab in addition to capecitabine compared with capecitabine alone. To 
maximise the available data for this study, the two bevacizumab arms of the trial were 
combined and are henceforth referred to as capecitabine plus bevacizumab.  
The primary outcome measure used in this study was quality adjusted progression free 
survival (QAPFS); with progression free survival (PFS) also reported. We used a 
similar approach to Cohn et al by using QAPFS time in place of the traditional quality 
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adjusted life year (QALY) as the measure of effectiveness in our analysis, as the MAX 
trial was not powered to assess effects on overall survival and estimates of this outcome 
were unreliable.
13
 We acknowledge that the use of PFS limits our ability to draw 
reasonable inferences regarding the incremental cost per QALY; however the inclusion 
of overall survival in a sensitivity analysis based on a set of plausible assumptions was 
intended to address this limitation. PFS was the primary endpoint of the MAX trial.
13
 
Further, the MAX trial was not powered to reliably assess the effects of treatment on 
overall survival. 
The time horizon of the analysis was the duration of the clinical trial, truncated at 18 
months, as more than 95% of patients had experienced the primary outcome 
(progression) by the end of the data collection period. Due to the relatively short time 
frame of the analysis, discounting of costs and health outcomes was not necessary. 
Patients: 
The cost effectiveness analysis included data from all patients who had completed a 
baseline and at least one on-study utility assessment. This resulted in 401 patients being 
included in the EuroQoL-5D (EQ-5D) analysis and 386 patients included in the Utility 
Based Quality of Life Questionnaire–Cancer (UBQ-C) analysis. Data was analysed on 
an intention-to-treat basis. There were 27 patients that did not complete any utility 
assessments (mostly due to inadequate English comprehension) who were excluded 
from the cost-effectiveness analysis. The impact of imputing missing utility values for 
the additional 42 patients that had completed an inadequate number of utility 
questionnaires was considered in a sensitivity analysis. 
Resource usage and costs: 
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Resource use was derived from individual patient data recorded in the MAX trial and 
costs are presented in 2011 Australian dollars. The specific resource use categories and 
sources are outlined in Table 1. Broadly, costs were obtained from standard Australian 
sources: the Pharmaceutical Benefits Schedule for drug costs
8
 and the Medicare 
Benefits Schedule
14
 for outpatient health services. Details of all hospital admissions 
throughout the trial were collected and costed based on Version 5.1 of the Australian 
Refined-Diagnosis Related Group (AR-DRG) cost weights
15
 using 3M Core Grouping 
Software. 
Both chemotherapy regimens were micro-costed using individual patient data and 
accounting for the total number of cycles required and the drug dosage per cycle.  
Because of the varying dosage quantities available for purchase, any drug wastage costs 
were negligible. The cost of administering intravenous chemotherapy in an outpatient 
clinic was also included. Routine follow up evaluations during treatment were costed 
per protocol until progression for each patient, which was assumed to be consistent with 
the level of resource use in standard practice.  
Unit costs were multiplied by resources used on a per patient basis. All costs were 
censored after disease progression. 
Utility scores and outcome measurement:  
The self reported EQ5D and UBQ-C questionnaires were prospectively collected to 
assess preference based measures of health status in the form of a utility score. Utility 
scores range from 0 (death) to 1 (full health). Responses from the EQ5D questionnaire 
produce utility values based on community preferences for health states,
16
 while utilities 
derived from the UBQ-C questionnaire are based on patient preferences.
17
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Both instruments were completed by patients at baseline, every 3 weeks for the first 12 
weeks, and then every 6 weeks until disease progression occurred. A median of 6 of 
each of the questionnaires were completed per patient up to 18 months, with average 
completion rates above 87% for both questionnaires. 
A QAPFS time over 18 months was calculated for each patient based on the methods 
described by Glasziou, Simes and Gelber
18
 and used in a similar study by Cohn et al.
13
 
For patients with missing utility scores, the last utility observation was carried forward.  
Sensitivity analysis: 
Bootstrap sampling with 1000 replications of individual cost and effect pairs was used 
to determine confidence intervals and the impact of uncertainty on the incremental cost-
effectiveness ratios.  
Results 
Base case: 
Table 2 displays the disaggregated cost components as measured in the study. Patients 
treated with capecitabine plus bevacizumab accumulated an average cost of $44,169 per 
patient from the beginning of treatment to time of progression, compared with an 
average of $14,577 for patients treated with capecitabine alone. The price of 
bevacizumab as listed in the Pharamceutical Benefits Schedule (PBS) was the main cost 
driver, comprising over 90% of the total cost difference between the two treatment 
arms.  The cost of routine follow up and hospitalisations were also lower in the 
capecitabine alone arm. 
An analysis of all hospitalisation episodes over the course of the trial (table 3) revealed 
that patients receiving capecitabine plus bevacizumab had a higher overall rate of 
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admissions than those receiving capecitabine alone. Patients in the bevacizumab arms 
had a lower proportion admissions directly related to their cancer, but a higher 
proportion related to treatment toxicity. The cost per hospital admission was 
approximately $2,646 higher in patients receiving capecitabine alone. However, the 
mean cost of hospitalisations per patient over the trial period was similar in both 
treatment groups. 
Table 4 displays the estimated utility scores for each arm, calculated using both the 
community valued EQ-5D questionnaire and the patient rated UBQ-C questionnaire. As 
expected, in both treatment groups, health states valued by patients were higher than 
those valued by the community. Utility scores were estimated to be marginally higher 
for the capecitabine alone group in both questionnaires. 
Results of the cost effectiveness analysis are displayed in Table 5.  Patients receiving 
capecitabine plus bevacizumab gained an additional 0.204 years (2.44 months) of PFS 
compared with patients receiving capecitabine alone, which translated to an additional 
0.154 years (1.85 months) of QAPFS when using community preferences, and 0.198 
years (2.37 months) of QAPFS when using patient preferences. QAPFS was higher in 
both arms when using the UBQ-C compared with the EQ-5D, with a statistically 
significant difference in QAPFS seen between the two arms when using the UBQ-C 
measure.  
In the base case analysis, the cost per progression free life year gained was $145,059. 
The cost per QAPFS year gained when using utility values obtained from the UBQ-C 
instrument was $149,455, which increased to $192,156 when using values from the EQ-
5D instrument. 
Sensitivity analysis 
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A simple decision analysis was conducted using a set of plausible assumptions to 
examine the likely impact of the treatment on cost-effectiveness in terms of overall 
survival. When making the assumptions that either 1) the survival time post progression 
was the same in both treatment groups or 2) survival time post progression was less for 
capecitabine plus bevacizumab (whereby post progression survival was offset by 50% 
of the total PFS gain) and 3) monthly costs post progression were the same for both 
treatment groups, capecitabine plus bevacizumab did not represent a cost effective 
treatment and our conclusions remained unchanged.  This result was robust to a 
relatively wide range of post progression cost estimates. 
The impact of extending the analysis to include the 443 patients that had completed an 
inadequate number of quality of life assessments (i.e. either no baseline or no on-study 
assessments) is presented in Table 6. The ICER for capecitabine plus bevacizumab was 
slightly more favourable in the larger group due to both lower incremental mean costs 
and an increased incremental QAPFS time. Nonetheless, the ICER remained above 
$100,000 per each additional year of PFS gained. In addition, the hazard ratio of the 
treatment effect for the subset of patients included in the analysis was not statistically 
different to the hazard ratio for the overall study. 
 
The impact of pooling data from the two bevacizumab arms of the trial was also 
examined in a sensitivity analysis. The cost effectiveness outcomes were not found to 
be significantly different when comparing capecitabine alone with either of the 
bevacizumab arms separately. While mitomycin C was associated with some additional 
costs related to toxicity, these costs were modest and the cost of mitomycin C itself was 
low. 
11 
 
Figure 1 displays the bootstrapped distribution of incremental cost effectiveness ratios. 
The cost effectiveness acceptability curves are presented in Figure 2, which depict the 
probability that each intervention will be cost effective given a range of cost 
effectiveness thresholds. The probability of the ICER falling below $100,000 per year 
of PFS or QAPFS gained was close to zero, demonstrating the robust nature of our 
conclusions. 
Discussion: 
In Australia, bevacizumab has received approval for government re-imbursement 
following a positive recommendation by the Pharmaceutical Benefits Advisory 
Committee (PBAC) which examines both the clinical effectiveness and cost-
effectiveness of new pharmaceutical treatments.  However, this is the first prospective 
study to evaluate the cost effectiveness of bevacizumab in metastatic colorectal cancer.  
Our results indicate that adding bevacizumab, with or without mitomycin C, to 
capecitabine monotherapy in patients with metastatic colorectal cancer exceeds 
AU$100,000 per quality adjusted PFS year gained (when applying the publicly listed 
price for bevacizumab in Australia) and is therefore unlikely to represent a cost 
effective use of health care resources in this context. Our results were estimated using 
individual level patient data and were robust to the effects of uncertainty. 
Our findings were consistent with retrospective studies that have estimated the cost 
effectiveness of bevacizumab in advanced colorectal cancer, either alone or in 
combination with other therapies.
9,10,12
 A 2008 meta analysis concluded that while 
bevacizumab has a significant effect on time to progression, there was no consensus on 
its cost-effectiveness in first-line therapy.
11
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Our study has a number of strengths. It is the first study to compare the cost-
effectiveness of bevacizumab in combination with capecitabine for colorectal cancer, 
and the first to collect data as part of a prospectively designed health economics study 
built into a phase III randomised controlled trial. Data were captured on all hospital 
admissions and their causes, an area of resource use which previous cost effectiveness 
studies of bevacizumab have not reported on.  A sensitivity analysis demonstrated that 
our results were highly robust to the effects of uncertainty in both the costs and effects 
of treatment.  
A limitationThe main limitation of our study is was that it did not produce an ICER in 
terms of overall survival or quality adjusted overall survival (QALYs) as are commonly 
used required by decision makers. The PFS analysis presented here was planned in 
advance of the MAX trial results as The theMAX trial was not powered to reliably 
assess the effects of treatment on overall survival. and estimates of this outcome were 
unreliable. In addition, the effectiveness measures presented here (PFS and QAPFS) 
reflect the fact that survival following progression on first line therapy is generally 
affected by individualisation of treatment and cross over effects.  We acknowledge that, 
as reported in our sensitivity analysis, the use of PFS may is likely to produce a more 
favourable cost effectiveness ratio than an ICER based on overall survival. However, 
given that the treatment was not found to be cost-effective we assume that the use of an 
OS endpoint would not alter our conclusions. A further limitation of this study is that no 
data were collected on health care utilisation outside of hospitalisations and routine 
follow up procedures, for example unscheduled outpatient visits, off-study 
pharmaceutical use or patient out of pocket costs. 
While there is no explicit threshold for an ICER at which a treatment is considered to be 
cost effective for funding purposes in Australia, a retrospective study found that PBAC 
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have historically been unlikely to recommend a drug for reimbursement if the ICER 
exceeded $100,000 per life year gained.
19
 The UK has a similar funding model to 
Australia, and preliminary NICE findings were recently reported as not supporting the 
use of bevacizumab in combination with oxaliplatin for the treatment of metastatic 
colorectal cancer,
20
 despite the fact that NICE has allowed for a higher cost-effective 
threshold when appraising end-of-life treatments.
21
  However, bevacizumab has been 
approved for the treatment of advanced colorectal cancer in Australia, Europe and the 
United States, based on its clinical effectiveness as demonstrated in prospective 
randomised studies.  The results of this study, along with other studies evaluating the 
cost-effectiveness of bevacizumab, highlight that in making funding decisions, 
governments may consider factors beyond the incremental cost-effectiveness ratios. 
Our analysis found that the main driver of the cost effectiveness outcome was the drug 
acquisition cost of bevacizumab. However, a key factor that remains unknown in these 
analyses is the extent of government negotiation of pharmaceutical pricing. The initial 
PBAC submission for the public reimbursement of bevacizumab was rejected on the 
grounds of an unacceptably high cost effectiveness ratio of between $105,000 and 
$200,000 per QALY gained
1
.
22
 A second submission following changes to the 
economic model (including a price decrease among other matters of concern) resulted 
in a new base case ICER of between $45,000 and $75,000 per QALY.
23
 Based on this 
result the PBAC recommended that a risk share arrangement be developed, which was 
accepted by the manufacturer. As details of the agreement remain confidential, the only 
option available in costing analyses is to use the publicly listed price. The capacity of a 
                                                             
1 Key differences between the analysis in the PBAC submissions and that presented here include the use 
of different combinations of drugs with bevacizumab (either 5-fluorouracil (FU)/leucovorin (LV) or 
irinotecan plus 5-FU/LV (IFL)), a different comparator group (patients treated with bolus irinotecan/5-
fluorouracil/leucovorin (IFL)) and the use of QALYs as the outcome measure. 
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pharmaceutical company to negotiate on price is unknown and likely to be influenced, 
at least in Australia, by currency fluctuations. 
An additional factor that may influence the cost effectiveness of chemotherapy 
treatments such as bevacizumab is the possibility of generic products coming onto the 
market once a pharmaceutical’s patent has expired. While this will not influence initial 
funding decisions of patented pharmaceuticals, the potential for the cost effectiveness 
ratio to improve over time is an important consideration when undertaking analyses of 
potentially effective but expensive drugs. In Australia, there is currently a mandatory 
16% price reduction on originator products with the introduction of a second brand. 
The use of both the EQ-5D and the UBQ-C utility instruments in this study allows 
comparisons to be made between community and patient preferences for health states. 
The patient valued UBQ-C instrument produced significantly higher utility values than 
the community valued EQ-5D, which is consistent with studies comparing patient 
versus community preferences and may reflect the human ability to ‘adapt’ over time to 
inferior health states.
24
 While the EQ5D produced a lower absolute utility value, this 
instrument reported a larger relative treatment effect (Table 5). Despite this, the UBQ-C 
analysis produced an ICER that was more than $40,000 less per QAPFS year than the 
EQ-5D analysis. While both ICERs remained beyond a reasonable threshold of cost 
effectiveness in this instance, this nonetheless highlights the influence that the choice of 
utility instrument can have over the cost effectiveness ratio.   
Although we have demonstrated that the use of bevacizumab was not cost effective in 
advanced colorectal cancer in the context of the MAX trial, the ICER could be 
significantly improved if a biomarker selecting a patient population who derive greater 
benefit with bevacizumab could be identified.  Efforts to identify such a biomarker for 
15 
 
bevacizumab have not been successful to date.  However, with other targeted therapies 
such as cetuximab, the use of a predictive biomarker had a significant impact on cost 
effectiveness.  Data from the CO17 trial showed that the ICER of cetuximab in 
metastatic colorectal cancer was reduced by almost half, from $299,613 per QALY in 
the entire study population to $186,761 per QALY gained in patients with wild type K-
Ras gene status.
25
 
In conclusion, given the high costs in relation to its clinical benefits, the addition of 
bevacizumab to capecitabine for the first-line treatment of metastatic colorectal was not 
found to be cost-effective in the MAX trial when using publicly listed pharmaceutical 
prices. As new information becomes available in relation to the cost of the treatment or 
a biomarker discovery this result may change and should be considered in future 
studies. Given the escalating cost of cancer care globally, it is important that future 
studies of new agents incorporate prospective cost effectiveness analyses in order to 
more effectively inform governments and other bodies making decisions in relation to 
drug re-imbursement. 
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Figure legends: 
Figure 1: Incremental cost effectiveness: PFS vs QAPFS (EQ5D and UBQC) 
 
Scatter plot depicting the bootstrapped incremental cost-effectiveness ratios (ICERs). 
Each point represents one of the 1000 iterations of the bootstrap and depicts the mean 
incremental cost and effectiveness of bevacizumab plus capecitabine compared with 
capecitabine alone. Red points represent ICERs calculated using progression free 
survival (PFS) as the effectiveness outcome,  green points using quality adjusted 
progression free survival (QAPFS) based on responses to the EQ-5D utility instrument 
and blue points using QAPFS based on responses to the UBQ-C utility instrument. 
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Figure 2: Cost effectiveness acceptability curves 
 
Cost-effectiveness acceptability curves for the bootstrapped ICERs plotted in Figure 1. 
Each curve represents the probability that bevacizumab plus capecitabine is cost-
effective compared with capecitabine alone based on a given threshold for the 
incremental cost-effectiveness ratio. The red curve represents the probability for ICERs 
calculated using progression free survival (PFS) as the effectiveness outcome,  the 
green curve using quality adjusted progression free survival (QAPFS) based on 
responses to the EQ-5D utility instrument and blue curve using QAPFS based on 
responses to the UBQ-C utility instrument. 
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Tables 
Please note: Tables 4 and 6 are to be online only 
 Table 1: Unit costs and sources 
Cost category 
Unit cost 
($) Source Item number 
Capecitabine    
Dosage: 1.25 g/m2 bd on day 1–14 every 3 weeks 1.39/mg PBS8 8362D 
    
Bevacizumab    
Dosage: 7.5 mg/kg starting day 1, every 3 weeks 4.30/mg CPAP26 5850X 
Intravenous administration: 30-90 mins 61.50 MBS14 13915 
    
Mitomycin C    
Dosage: 7 mg/m2 on day 1 and every 6 weeks, with a 
maximum dose of 14 mg and for only four treatments  5.24/mg 
Austin 
Pharmacy  
Intravenous administration: 15 mins 61.50 MBS 13915 
    
Routine follow up/imaging    
History and physical exam 72.65 MBS 116 
Haematology 17.05 MBS 65070 
Biochemistry 17.80 MBS 66512 
Tumour markers 24.50 MBS 66650 
CT scan 560.00 MBS 56807 
    
In patient hospital admissions    AR-DRG 15  Version 5.1 
PBS = Pharmaceutical Benefits Scheme, CPAP = Chemotherapy Pharmaceutical 
Access Program, MBS = Medicare Benefits Schedule, AR-DRG = Australian Refined 
Diagnosis Related Groups 
 
Table 2: Disaggregated costs 
Cost category 
Mean cost per patient in 
capecitabine alone 
Mean cost per patient 
in  capecitabine + 
bevacizumab Difference 
Treatment drug cost $5,182 $32,443 $27,262 
Drug administration cost $0 $672 $672 
Routine follow up procedures $3,778 $5,345 $1,567 
Hospitalisations $5,617 $5,709 $92 
Total $14,577 $44,169 $29,592 
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Table 3 Inpatient hospitalisation costs 
Hospitalisations 
Capecitabine 
alone 
Capecitabine + 
bevacizumab Difference 
Mean number of admissions per patient on study 0.62 0.88 0.26 
Proportion of patients with at least one admission 39% 51% 12% 
Type of admissions:    
Cancer related admissions 47% 30% -17% 
Treatment related admissions 26% 38% 12% 
Other admissions 27% 32% 5% 
Mean length of stay per admission (days) 10.4 7.2 -3.22 
Mean cost per admission $9,153 $6,507 -$2,646 
Mean cost of hospitalisations per patient on study $5,617 $5,709 $92 
 
 
Table 4 Utility scores for capecitabine alone versus capecitabine plus bevacizumab 
[Online only] 
  Capecitabine 
Capecitabine + 
Bevacizumab Difference 
EQ-5D* 0.7939 0.7839 -0.01 
UBQ-C* 0.9389 0.9379 -0.001 
*With adjustment for baseline EQ5D utility 
 
Table 5: Results of the cost effectiveness analysis 
  
Capecitabine 
alone 
Capecitabine + 
bevacizumab Difference ICER ($)  
Cost  14,577 44,169 29,592  
95% CI 
12,041 - 
18,129 41,209 - 46,979 25,089 - 33,388  
PFS years 0.562 0.766 0.204 145,059 
95% CI 
0. 496 - 
0.625 0. 714 - 0.812 0. 120 - 0.283 106,703 - 233,225 
QAPFS years (EQ-5D) 0.446 0.600 0.154 192,156 
95% CI 
0. 391 - 
0.498   0. 553 - 0.640 0.085 - 0.223 135,619 - 326,894 
QAPFS years (UBQ-C) 0.531 0.729 0.198 149,455 
95% CI 
0.467 - 
0.592 0.681 - 0.773 0.122- 0.276 100,356 – 245,910 
PFS = progression free survival, QAPFS = quality adjusted progression free survival, 
ICER = incremental cost effectiveness ratio 
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Table 6 Comparison of results when including patients with only one EQ-5D utility 
assessment 
[Online only] 
 401 patients 443 patients 
Incremental differences Mean 95% CI Mean 95% CI 
Cost ($) 29,592 25,089 - 33,388 26,569 22,879 - 30,116 
PFS years 0.204 0. 120 - 0.283 0.221 0.130 - 0.302 
ICER: PFS ($) 145,059 106,703 - 233,225 120,159 89,872 - 189,778 
QAPFS years (EQ5D) 0.154 0.085 - 0.223 0.158 0.087 - 0.240 
ICER: QAPFS ($) 192,156 135,619 - 326,894 167,901 115,691 - 283,709 
PFS = progression free survival, ICER = incremental cost effectiveness ratio, QAPFS = 
quality adjusted progression free survival 
 
 
 
 
   
 
 
 
